Kasheika McNeill, NP
Gerontology · Woodbridge, VANPI 1649817016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $782, 3.0 times the $259 reported in 2021.
Across 66 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$238
- Novartis$224
- Redhill Biopharma Inc.$153
- Novo Nordisk$116
- E.r. Squibb & Sons, L.L.C.$98
- Merck$93
- plus $642 from 15 others
What the payments were for
- Food & beverage$1,564100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 5 | $238 |
| Novartis | 13 | $224 |
| Redhill Biopharma Inc. | 6 | $153 |
| Novo Nordisk | 5 | $116 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Merck | 4 | $93 |
| Scpharmaceuticals Inc. | 3 | $90 |
| Boehringer Ingelheim | 3 | $66 |
| Scilex Pharmaceuticals Inc. | 4 | $65 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $59 |
| AstraZeneca | 2 | $53 |
| Lilly USA, LLC | 2 | $42 |
| Boston Scientific | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $40 |
| Heartflow, Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Abiomed | 1 | $20 |
| Pfizer | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$163
- MOVANTIK$125
How this compares
$1,564 in reported general payments places this provider in the 75th percentile of 130 gerontology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 115 | $147,071 |
| ZtlidoLidocaine | 67 | $43,776 |
| MovantikNaloxegol Oxalate | 61 | $23,914 |
| FarxigaDapagliflozin Propanediol | 18 | $20,285 |
| EliquisApixaban | 21 | $15,827 |
| BelbucaBuprenorphine Hcl | 18 | $14,266 |
| Xtampza ErOxycodone Myristate | 37 | $13,109 |
| EntrestoSacubitril/Valsartan | 16 | $12,213 |
| Hysingla ErHydrocodone Bitartrate | 29 | $11,872 |
| ButransBuprenorphine | 12 | $4,803 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 241 | $4,491 |
| Naloxone Hcl | 53 | $3,361 |
| Ibuprofen-FamotidineIbuprofen/Famotidine | 14 | $2,629 |
| Lidocaine | 23 | $2,557 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 96 | $2,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Ztlido | $65 | $43,77667 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $18 | $27,37555 claims |
| Redhill Biopharma Inc.Movantik | $153 | $23,91461 claims |
| AstraZenecaFarxiga | $53 | $20,28518 claims |
| PfizerEliquis | $20 | $15,82721 claims |
| NovartisEntresto | $224 | $12,21316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 130 gerontology providers in Virginia.
Other gerontology in Woodbridge
- Lauren FerrisRoanoke$11K
- Catherine RatliffCharlottesville$10K
- Jennifer TaylorAbingdon$9K
- Alexander KingCharlottesville$7K
- Margaret HeidenreichChantilly$6K
- Jillian MaurielloRichmond$6K
- Christine HowellNorfolk$6K
- Molly McCrackenRichmond$5K
- Meredith OverstreetManassas$5K
- Danielle JenningsRichmond$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.